Filtered By:
Condition: Asthma
Drug: Flonase
This page shows you your search results in order of date.
Order by Relevance | Date
Total 230 results found since Jan 2013.
The Comparative Bioavailability of Fluticasone and Azelastine Delivered as a Single Fixed Dose Combination (MP-AzeFlu) in Comparison to Two Different Formulations of Azelastine and Fluticasone Propionate Following Intranasal Administration in Healthy Chinese Volunteers
Source: Journal of Asthma and Allergy - June 30, 2023 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
The Rising Cost of Rhinologic Medications
CONCLUSION: The rising cost of highly utilized medications contribute to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations.PMID:37098404 | DOI:10.1016/j.anai.2023.04.013
Source: Annals of Allergy, Asthma and Immunology - April 25, 2023 Category: Allergy & Immunology Authors: Milind Vasudev Sina J Torabi Lauren Michelle Leo L T Meller Jack L Birkenbeuel Kelsey M Roman Theodore V Nguyen Edward C Kuan Source Type: research
Relationship between medication adherence and self-assessment responses in patients with asthma
Digital inhalers can help patients and healthcare professionals identify poor maintenance medication adherence in patients with asthma. Digihaler integrated inhalers transmit data wirelessly to a smart phone application (App), which allows for inhaler usage tracking. The App includes a voluntary, non-respiratory-specific, daily self-assessment (DSA). The CONNECT2 study (NCT04677959) compared the Digihaler Maintenance and Reliever Digital System (MRDS; fluticasone propionate/salmeterol and albuterol Digihalers) with standard of care (SoC) maintenance and reliever inhalers in participants with asthma.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Giselle Mosnaim, Flavia Hoyte, Michael Wechsler, Guilherme Safioti, Katja Sagalovich, Randall Brown, Michael Depietro, Tanisha Hill Source Type: research
Relationship between short-acting beta-agonist use and self-assessment responses in patients with asthma
Digital inhalers have the potential to help improve clinical outcomes by providing information about over-reliance on short-acting beta2-agonist (SABA). Digihaler integrated inhalers transmit data wirelessly to a smart phone application (App), which allows for tracking of inhaler usage. The App includes a voluntary, non-respiratory-specific, daily self-asse ssment (DSA). The 6-month CONNECT2 study (NCT04677959) compared the Digihaler Maintenance and Reliever Digital System (MRDS; fluticasone propionate/salmeterol and albuterol Digihalers) with standard of care (SoC) maintenance and reliever inhalers in participants with asthma.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Flavia Hoyte, Giselle Mosnaim, Michael Wechsler, Guilherme Safioti, Katja Sagalovich, Randall Brown, Michael Depietro, Tanisha Hill Source Type: research
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma
Source: Journal of Asthma and Allergy - January 19, 2023 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Does Omalizumab lead to sustained improvement in Asthma Control?
Conclusion: Omalizumab improved asthma control in some patients, but many still remained sub optimally controlled. Other variables are likely to influence asthma control.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Gregson, E., Tang, A., Brookman, S., Tarr, J., Amin, A., Shenoy, A., Kansra, S., Murray, C., Gupta, A. Tags: 07.02 - Paediatric asthma and allergy Source Type: research
Objective measurement of adherence to asthma treatment with a maintenance and reliever digital system
Suboptimal adherence to inhaled maintenance therapy is common among patients with asthma. In the Maintenance and Reliever Digital System (MRDS), the Digihaler integrated inhalers (fluticasone propionate/salmeterol [FS] and albuterol Digihalers) transmit data wirelessly to a mobile application, which synchronizes with a Digital Health Platform to store and transfer data to a web-based Dashboard. The 6-month CONNECT2 study (NCT04677959) evaluated the MRDS in comparison with the standard of care (SoC) maintenance and reliever inhalers in participants with asthma aged ≥13 years with suboptimal asthma control (Asthma Control Test score
Source: Annals of Allergy, Asthma and Immunology - November 1, 2022 Category: Allergy & Immunology Authors: G. Mosnaim, F. Hoyte, G. Safioti, R. Brown, T. Li, M. DePietro, T. Hill, M. Wechsler Tags: P100 Source Type: research
Data from a maintenance and reliever digital system support patient –clinician interactions in asthma
In the Maintenance and Reliever Digital System (MRDS), the Digihaler integrated inhalers (fluticasone propionate/salmeterol and albuterol Digihalers) transmit data wirelessly to a mobile application, which transfers data to a web-based Dashboard. The 6-month CONNECT2 study (NCT04677959) evaluated the MRDS in participants aged ≥13 years with suboptimal asthma control (Asthma Control Test score
Source: Annals of Allergy, Asthma and Immunology - November 1, 2022 Category: Allergy & Immunology Authors: G. Mosnaim, F. Hoyte, G. Safioti, R. Brown, T. Li, M. DePietro, T. Hill, M. Wechsler Tags: P098 Source Type: research
Effectiveness of a maintenance and reliever digital system to improve asthma control
In the Maintenance and Reliever Digital System (MRDS), Digihaler integrated inhalers (fluticasone propionate/salmeterol and albuterol Digihalers) transmit data wirelessly to a mobile application, which synchronizes with a Digital Health Platform to store and transfer data to a web-based Dashboard. This allows patients and clinicians to track and review inhaler usage and inhalation quality as part of clinical decision making. The CONNECT2 study (NCT04677959) evaluated asthma control as measured by the Asthma Control Test (ACT) in participants using the MRDS versus participants using the standard of care (SoC) maintenance and reliever inhalers.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2022 Category: Allergy & Immunology Authors: G. Mosnaim, F. Hoyte, G. Safioti, R. Brown, T. Li, M. DePietro, T. Hill, M. Wechsler Tags: P097 Source Type: research
Randomized, controlled trial of exhalation delivery system with fluticasone for chronic rhinosinusitis without nasal polyps
There are no FDA-approved medications for the>20 million chronic rhinosinusitis patients without nasal polyps. The Exhalation Delivery System with Fluticasone (EDS-FLU) is an intranasal steroid in a device that delivers drug to regions above the inferior turbinate and behind the nasal valve.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2022 Category: Allergy & Immunology Authors: A. Peters Tags: P217 Source Type: research
Review of evidence supporting the use of nasal corticosteroid irrigation for chronic rhinosinusitis
CONCLUSION: Designing more robust clinical trials may help determine if CSI is a valid treatment option. Until more evidence supporting CSI use exists, health care professionals should strongly consider choosing FDA-approved therapies for the treatment of CRS.PMID:36116748 | DOI:10.1016/j.anai.2022.09.008
Source: Annals of Allergy, Asthma and Immunology - September 18, 2022 Category: Allergy & Immunology Authors: Jonathan A Bernstein Andrew A White Joseph K Han David M Lang David Elkayam Fuad M Baroody Source Type: research
Efficacy and Safety of Fluticasone Furoate and Oxymetazoline Nasal Spray: A Novel First Fixed Dose Combination for the Management of Allergic Rhinitis with Nasal Congestion
Source: Journal of Asthma and Allergy - June 10, 2022 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
The Effects of Combined Therapeutic Protocol on Allergic Rhinitis Symptoms and Molecular Determinants
Iran J Allergy Asthma Immunol. 2022 Apr 11;21(2):141-150. doi: 10.18502/ijaai.v21i2.9222.ABSTRACTCurrent medications to treat allergic rhinitis (AR) include antihistamines, corticosteroids, and anti-leukotrienes. In the present study, we investigated the effects of combination therapy; using these drugs, and evaluates the AR-related markers and parameters in an animal model. After inducing BALB/c mice AR models, the animals were treated with either pranlukast, loratadine, fluticasone, loratadine + fluticasone, loratadine + pranlukast, fluticasone + pranlukast, or loratadine + fluticasone + pranlukast. Clinical symptoms, Im...
Source: Iranian Journal of Allergy, Asthma and Immunology - May 1, 2022 Category: Allergy & Immunology Authors: Yuanfeng Shen Entezar Mehrabi Nasab Fatemeh Hassanpour Seyyed Shamsadin Athari Source Type: research
